CV Sciences Q1 revenue down 11.4% to $3.2M; adjusted EBITDA loss narrows to $0.1M

CV Sciences, Inc.

Revenue $3.2M (down 11.4% YoY); unit sales down 12.2%, partially offset by minor price increases.
Gross margin improved to 48.9% (from 46.0% YoY); operating loss $0.3M vs prior year operating income due to $0.5M payroll tax reversal.
Adjusted EBITDA loss of $0.1M vs $0.3M loss in Q1 2025; cash balance $0.3M at quarter end.
Completed debt restructuring to strengthen financial position; launched EMPOWR plant-based protein/creatine formula.
New products launched since Jan 2023 contributed 43% of Q1 net revenue; 45 new products introduced.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.